Literature DB >> 11564812

Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens.

X F Bai1, J Bender, J Liu, H Zhang, Y Wang, O Li, P Du, P Zheng, Y Liu.   

Abstract

Cytotoxic T cells recognize tumor Ags and destroy cancer cells in vitro. Adoptive transfer studies with transgenic T cells specific for tumor Ags have demonstrated that CTL are effective only in mice with small tumor burdens and thus appear to have limited potential in cancer immunotherapy. Here we used transgenic mice that express the TCR specific for an unmutated tumor Ag P1A and multiple lineages of P1A-expressing tumors to address this critical issue. We found that local costimulation, either by expression of B7-1 on the tumor cells or by local administration of anti-CD28 mAb 37N, reinvigorated the function of CTL specific for the tumor Ag, as it substantially increased the efficacy of CTL therapy for mice with large tumor burdens. Our study suggests that CTL-based immunotherapy can be manipulated to deal with large tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564812     DOI: 10.4049/jimmunol.167.7.3936

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses.

Authors:  H Voigt; D Schrama; A O Eggert; C S Vetter; K Müller-Blech; H M Reichardt; M H Andersen; J C Becker; F Lühder
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  Immune competence of cancer-reactive T cells generated de novo in adult tumor-bearing mice.

Authors:  Kenneth F May; Kenneth Lute; Ergun Kocak; Shahab Abdessalam; Lijie Yin; Ou Li; Zhen Guan; Gary Philips; Pan Zheng; Yang Liu
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

4.  IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.

Authors:  L-X Wang; F Talebian; J-Q Liu; M Khattabi; L Yu; X-F Bai
Journal:  Scand J Immunol       Date:  2012-03       Impact factor: 3.487

5.  Effect of bone marrow-derived monocytes transfected with RNA of mouse colon carcinoma on specific antitumor immunity.

Authors:  Xiao-Yuan Chu; Long-Bang Chen; Jing Zang; Jing-Hua Wang; Qun Zhang; Huai-Cheng Geng
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

6.  Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.

Authors:  Jin-Qing Liu; Pramod S Joshi; Chuansong Wang; Hani Y El-Omrani; Yi Xiao; Xiuping Liu; John P Hagan; Chang-Gong Liu; Lai-Chu Wu; Xue-Feng Bai
Journal:  J Immunol       Date:  2010-04-19       Impact factor: 5.422

7.  Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.

Authors:  Lixin Wang; Jin-Qing Liu; Fatemeh Talebian; Hani Y El-Omrani; Mazin Khattabi; Li Yu; Xue-Feng Bai
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

8.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.

Authors:  Ailin Bai; Eileen Higham; Herman N Eisen; K Dane Wittrup; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

9.  Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy.

Authors:  R K Sharma; E S Yolcu; K G Elpek; H Shirwan
Journal:  Cancer Gene Ther       Date:  2010-06-18       Impact factor: 5.987

10.  Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.

Authors:  Li-Xin Wang; Zhen-Yang Mei; Ji-Hao Zhou; Yu-Shi Yao; Yong-Hui Li; Yi-Han Xu; Jing-Xin Li; Xiao-Ning Gao; Min-Hang Zhou; Meng-Meng Jiang; Li Gao; Yi Ding; Xue-Chun Lu; Jin-Long Shi; Xu-Feng Luo; Jia Wang; Li-Li Wang; Chunfeng Qu; Xue-Feng Bai; Li Yu
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.